lyra therapeutics, inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. the company's xtreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. its product candidates include lyr-210 and lyr-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. the company was formerly known as 480 biomedical, inc. and changed its name to lyra therapeutics, inc. in july 2018. lyra therapeutics, inc. was founded in 2005 and is headquartered in watertown, massachusetts.
Company profile
Ticker
LYRA
Exchange
Website
CEO
Maria Palasis
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
480 Biomedical, Inc., Arsenal Medical, Inc., Arsenal Vascular, Inc., WMR Biomedical Inc
SEC CIK
Corporate docs
Subsidiaries
Lyra Therapeutics Security Corporation ...
LYRA stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
19 Apr 24
EFFECT
Notice of effectiveness
2 Apr 24
S-8
Registration of securities for employees
22 Mar 24
S-3
Shelf registration
22 Mar 24
10-K
2023 FY
Annual report
22 Mar 24
8-K
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
21 Mar 24
8-K
Departure of Directors or Certain Officers
1 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Entry into a Material Definitive Agreement
28 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
18 Dec 23
Latest ownership filings
4
Harlan Waksal
20 Mar 24
4
Maria Palasis
20 Mar 24
SC 13G/A
PURA VIDA INVESTMENTS, LLC
15 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
SC 13D/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G
Vestal Point Capital, LP
13 Feb 24
4
John E Bishop
1 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.24 mm | 26.24 mm | 26.24 mm | 26.24 mm | 26.24 mm | 26.24 mm |
Cash burn (monthly) | 9.84 mm | 7.06 mm | 5.61 mm | 5.48 mm | 4.70 mm | 4.70 mm |
Cash used (since last report) | 65.65 mm | 47.12 mm | 37.43 mm | 36.59 mm | 31.40 mm | 31.37 mm |
Cash remaining | -39.41 mm | -20.87 mm | -11.19 mm | -10.35 mm | -5.16 mm | -5.13 mm |
Runway (months of cash) | -4.0 | -3.0 | -2.0 | -1.9 | -1.1 | -1.1 |
Institutional ownership, Q3 2023
35.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 34 |
Opened positions | 7 |
Closed positions | 17 |
Increased positions | 8 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 27.17 bn |
Total shares | 20.88 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
NBVM GP | 5.89 mm | $15.13 mm |
Venrock Healthcare Capital Partners II | 3.43 mm | $0.00 |
Samsara BioCapital | 2.78 mm | $17.21 mm |
Armistice Capital | 1.55 mm | $6.06 bn |
Pura Vida Investments | 1.41 mm | $5.53 bn |
Ikarian Capital | 1.25 mm | $4.90 bn |
Polaris Venture Partners V | 1.10 mm | $0.00 |
VR Adviser | 924.17 k | $3.61 bn |
Intersouth Partners Vii L P | 738.20 k | $0.00 |
Soleus Capital Management | 592.42 k | $2.32 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Mar 24 | Waksal Harlan | Common Stock | Grant | Acquire A | No | No | 0 | 275,000 | 0.00 | 536,966 |
18 Mar 24 | Maria Palasis | Stock Option Common Stock | Grant | Acquire A | No | No | 5.77 | 500,000 | 2.89 mm | 500,000 |
30 Jan 24 | John E Bishop | Stock Options Common Stock | Grant | Acquire A | No | No | 4.58 | 200,000 | 916.00 k | 200,000 |
30 Jan 24 | Richard Nieman | Stock Options Common Stock | Grant | Acquire A | No | No | 4.58 | 200,000 | 916.00 k | 200,000 |
30 Jan 24 | Jason Cavalier | Stock Options Common Stock | Grant | Acquire A | No | No | 4.58 | 200,000 | 916.00 k | 200,000 |
Press releases
Thinking about buying stock in GameStop, Equinix, Lyra Therapeutics, Krystal Biotech, or KULR Technology?
26 Mar 24
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
21 Mar 24
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1 Mar 24